Silence Therapeutics to make regulatory filing for lead cancer therapy
04 December 2008
Biopharmaceutical company Silence Therapeutics is planning to submit a clinical trial application (CTA) for its leading drug candidate by the end of December. The company is also in talks with several third parties over possible funding options for the new drug.
Silence specialises in RNA interference technology, which selectively “silences” genes linked to the onset of disease. The company said the decision to put forward the application for Atu027 followed a board review of progress with the drug and, in particular, consideration of recent discussions with BfArM, the German regulator for drugs and medical devices.
Atu027 is a small interfering RNA (siRNA) molecule that is being developed for the systemic treatment of cancer.
Silence anticipates commencing its Phase 1b human clinical study of Atu027 in cancer patients in 2009, provided the relevant approvals are forthcoming.
Elsewhere, Silence confirmed that it was actively considering a range of collaborations and partnerships and while these discussions progress, it was managing its cash reserves prudently in order to fund its ongoing activities.
It also confirmed that it had identified a number of new targets and indication opportunities that it intends to progress in 2009.
|
Relevant Companies
For more Company information and share price data click below:
|